Stéphane Boissel to Lead SparingVision as Chief Executive Officer
SparingVision has hired Stéphane Boissel as its newest Chief Executive Officer. Previously, Stéphane served Sangamo Therapeutics as Executive Vice President of Corporate Strategy. Stéphane brings extensive industry and leadership experience, having served as Chief Executive Officer for TxCell and Genclis, as well as Deputy Chief Executive Officer for Transgene and Innate Pharma.
SparingVision is a biotechnology company based in Paris, France that is focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is a spin-off of the Paris Vision Institute.